Tandem Diabetes Care, Inc. (TNDM) is a Medical - Devices company in the Healthcare sector, currently trading at $20.66. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is TNDM = $31 (+47.6% upside).
Valuation: TNDM trades at a trailing Price-to-Earnings (P/E) of -6.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.06.
Financials: revenue is $1.0B, +9%/yr average growth. Net income is $205M (loss), growing at -63.9%/yr. Net profit margin is -20.2% (negative). Gross margin is 52.3% (+0.8 pp trend).
Balance sheet: total debt is $444M against $155M equity (Debt-to-Equity (D/E) ratio 2.86, leveraged). Current ratio is 2.55 (strong liquidity). Debt-to-assets is 50.4%. Total assets: $881M.
Analyst outlook: 24 / 39 analysts rate TNDM as buy (62%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 74/100 (Pass), Growth 40/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 70/100 (Pass), Future 73/100 (Pass), Income 10/100 (Fail).
